Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Wait and take the next dose around your next meal as usual
These trials were both stopped early due to clinical benefit
News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
Wegovy and cardiovascular risk reduction In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
This reduction may compromise the liver's ability to manage oxidative stress and perform detoxification, potentially contributing to disease progression
